Myalgia Clinical Trial
Official title:
Comparative Evaluation of Continuous and Pulse Mode of Ultrasound Therapy in Myalgia of Maxillofacial Region
Verified date | March 2023 |
Source | Postgraduate Institute of Dental Sciences Rohtak |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pain and trismus caused by Myalgia in masticatory muscles are one of the prime concerns for the patients. Various studies have been performed using US therapy for myofascial pain syndrome of head & neck region. US is a non-invasive frequently used physical agent which increase blood flow in tissues and collagen fibers ability to grow, & reduce muscle spasm with its thermal effect. It is difficult to imply the results of studies performed in muscles of other regions of body to the maxillofacial region because of the superficial placement of these muscles.US is being frequently used for myofascial pain, but there is an absence of a consensus regarding the frequency and mode of administration available in literature for administration of this therapy in maxillofacial region. Therefore, the present study has been designed to compare the therapeutic effect of two modes of US i.e., continuous and pulsed at 3 MHz frequency
Status | Completed |
Enrollment | 80 |
Est. completion date | October 15, 2022 |
Est. primary completion date | October 15, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Patients diagnosed with myalgia within orofacial muscle as per DC/TMD (Ia and Ib) 2. Patient's consent for participation in this study. Exclusion Criteria: 1. Patients with epilepsy/seizures 2. Patients with radiographic changes suggestive of pathological conditions of temporomandibular joint (TMJ). 3. Patients with undiagnosed orofacial pain 4. Any sort of skin lesion at the site where electrode is to be placed. 5. Therapeutic ultrasound must not be applied over areas of impaired circulation, ischemic areas, or areas having sensory deficit. 6. Sites of active infection 7. Patients with metal prosthesis 8. Patients with Becks depression score >25 will be excluded. |
Country | Name | City | State |
---|---|---|---|
India | PGIDS | Rohtak | Haryana |
Lead Sponsor | Collaborator |
---|---|
Postgraduate Institute of Dental Sciences Rohtak |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the intensity of pain in each group | Visual Analog Scale (VAS) 0n a scale of 0-10 | Base line | |
Primary | To evaluate the intensity of pain in each group | Visual Analog Scale (VAS) 0n a scale of 0-10 | 2 weeks | |
Primary | To evaluate the intensity of pain in each group | Visual Analog Scale (VAS) 0n a scale of 0-10 | 4weeks | |
Primary | To evaluate the intensity of pain in each group | Visual Analog Scale (VAS) 0n a scale of 0-10 | 6 weeks | |
Primary | To evaluate the intensity of pain in each group | Visual Analog Scale (VAS) 0n a scale of 0-10 | 3 months | |
Primary | To assess pressure pain sensitivity of muscles in the two groups. | Algometer | Base line | |
Primary | To assess pressure pain sensitivity of muscles in the two groups. | Algometer | 2 weeks | |
Primary | To assess pressure pain sensitivity of muscles in the two groups. | Algometer | 4 weeks | |
Primary | To assess pressure pain sensitivity of muscles in the two groups. | Algometer | 6 weeks | |
Primary | To assess pressure pain sensitivity of muscles in the two groups. | Algometer | 3 months | |
Secondary | To evaluate the maximal mouth opening and functional movements | Digital Vernier calliper | Base line | |
Secondary | To evaluate the maximal mouth opening and functional movements | Digital Vernier calliper | 2 weeks | |
Secondary | To evaluate the maximal mouth opening and functional movements | Digital Vernier calliper | Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment | |
Secondary | To evaluate patient psychological status | Beck depression inventory | Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment | |
Secondary | To evaluate quality of life | Oral Health Impact Profile (OHIP 14) | Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment | |
Secondary | To assess the need for pain medication | number of medication needed | Base line ,2 weeks,4 weeks ,6 weeks, 3 months post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02362685 -
Metabolic Exercise Testing
|
||
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|
||
Recruiting |
NCT03849534 -
Treatment of Temporomandibular Disorders in Children and Adolsecents
|
N/A | |
Completed |
NCT04897581 -
BBTI vs PSR in Musculoskeletal Orofacial Pain Adults
|
N/A | |
Completed |
NCT00957996 -
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
|
Phase 3 | |
Completed |
NCT04581395 -
The Effect of Pretreatment With Roc on Succinylcholine Myalgias
|
Phase 3 | |
Completed |
NCT01026311 -
Coenzyme Q10 in Older Athletes Treated With Statin Medications
|
Phase 4 | |
Completed |
NCT01506583 -
Clinical Evaluation of QFlu Combo Test
|
||
Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
Terminated |
NCT02685202 -
Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea
|
N/A | |
Completed |
NCT01279590 -
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
|
Phase 2 | |
Recruiting |
NCT04806191 -
Simple and Evidence-based Examination and Treatment of Shoulder Pain in General Practice
|
N/A | |
Enrolling by invitation |
NCT06405646 -
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin
|
||
Not yet recruiting |
NCT01097798 -
To Evaluate the Efficacy and Safety Aliviador Compared to Gelol in Patients With Contusions, Sprains, Trauma and Muscle Injury.
|
Phase 3 | |
Not yet recruiting |
NCT05961501 -
The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin
|
Phase 2/Phase 3 | |
Completed |
NCT05448209 -
The Effect of Walking Exercise Based on TOUS on Peripheral Neuropathy and Arthralgia-Myalgia in Women With Breast Cancer
|
N/A | |
Not yet recruiting |
NCT03566394 -
Prophylactic Gabapentin for Taxane-Induced Arthralgia and Myalgia Syndrome in Breast Cancer Patients Undergoing Adjuvant Chemotherapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04426123 -
Masseter Myofascial Pain Relief Following an Intra-muscular Injection With Botulinum Toxin Type A.
|
Phase 2 | |
Completed |
NCT04737278 -
Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
|
Phase 1/Phase 2 | |
Recruiting |
NCT06125002 -
Diosmin for Treatment of Delayed-onset Muscle Soreness (DOMS)
|
Phase 1 |